Physician profile
Bethany King
NPI 1497301139
$11,267.32
in general payments reported to CMS, 2019-2025
63 companies · $2,441 in 2025
The $2,441 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,093 · 2022: $1,501 · 2023: $2,619 · 2024: $2,614 · 2025: $2,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,657 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,656.93 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,235.85 | 2021-2025 | Piqray, Kisqali |
| Merck Sharp & Dohme LLC | $974.86 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Celgene Corporation | $831.52 | 2021-2025 | Reblozyl, Pomalyst, Opdivo |
| Astrazeneca Pharmaceuticals LP | $794.27 | 2021-2025 | Calquence, Imfinzi, Enhertu |
| Myriad Genetic Laboratories, INC. | $488.29 | 2021-2025 | Myrisk |
| Janssen Biotech, INC. | $466.06 | 2021-2025 | Erleada, Darzalex, Balversa |
| Amgen INC. | $385.11 | 2021-2023 | Vectibix, Xgeva, Nplate |
| Regeneron Healthcare Solutions, INC. | $338.36 | 2022-2025 | Libtayo |
| Eisai INC. | $323.28 | 2021-2025 | |
| Genzyme Corporation | $322.78 | 2021-2025 | |
| Lilly USA, LLC | $282.46 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Incyte Corporation | $256.86 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Beone Medicines USA, INC. | $253.89 | 2025 | Brukinsa, Tevimbra |
| Daiichi Sankyo INC. | $251.92 | 2021-2025 | Enhertu, Datroway |
| Genentech USA, INC. | $245.23 | 2023-2025 | Polivy, Lunsumio, Columvi |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $230.14 | 2021-2025 | Reblozyl, Opdivo |
| Pfizer INC. | $221.36 | 2021-2025 | |
| Tersera Therapeutics LLC | $215.73 | 2023-2025 | Zoladex |
| Ipsen Biopharmaceuticals, INC | $207.02 | 2021-2024 | Onivyde, Somatuline Depot |
| Glaxosmithkline, LLC. | $189.49 | 2021-2025 | Ojjaara, Jemperli |
| Puma Biotechnology, INC. | $171.78 | 2022-2025 | |
| Array Biopharma INC | $168.82 | 2022-2025 | Braftovi, Mektovi, Tukysa |
| Beigene USA, INC. | $142.15 | 2021-2025 | Brukinsa, Tevimbra |
| Deciphera Pharmaceuticals INC. | $129.49 | 2021-2025 | Qinlock, Romvimza |
| Bayer Healthcare Pharmaceuticals INC. | $129.44 | 2021-2025 | |
| Abbvie INC. | $127.96 | 2023-2025 | |
| Aveo Pharmaceuticals, INC. | $112.29 | 2022-2025 | |
| Argenx US, INC. | $111.10 | 2024 | Vyvgart Hytrulo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.02 | 2021-2023 | Gilotrif |
| Astellas Pharma US INC | $99.47 | 2021-2024 | Xtandi, Padcev |
| Karyopharm Therapeutics INC. | $96.91 | 2021-2025 | Xpovio |
| Seagen INC. | $91.90 | 2022-2023 | Adcetris |
| Pharmaessentia USA Corporation | $88.58 | 2023-2024 | Besremi |
| Pharmacyclics LLC, An Abbvie Company | $79.68 | 2022 | |
| Exelixis INC. | $75.45 | 2022-2023 | Cabometyx |
| Takeda Pharmaceuticals U.S.A., INC. | $70.18 | 2022-2025 | Alunbrig, Ninlaro |
| Blueprint Medicines Corporation | $69.77 | 2023-2024 | Ayvakit |
| Alexion Pharmaceuticals, INC. | $66.82 | 2022-2025 | Ultomiris |
| Jazz Pharmaceuticals INC. | $66.82 | 2021-2025 | |
| Servier Pharmaceuticals LLC | $63.56 | 2023-2024 | |
| Adaptive Biotechnologies Corporation | $60.30 | 2024-2025 | Clonoseq |
| Taiho Oncology, INC. | $60.18 | 2021-2025 | |
| Rigel Pharmaceuticals, INC. | $48.82 | 2021-2024 | Tavalisse, Rezlidhia |
| Pharmacosmos Therapeutics INC. | $47.00 | 2022-2025 | Monoferric |
| Stemline Therapeutics INC. | $46.68 | 2023-2025 | Orserdu |
| Sumitomo Pharma America, INC. | $46.32 | 2023-2025 | Orgovyx |
| Heron Therapeutics, INC. | $40.99 | 2022 | |
| Sobi, INC | $36.23 | 2022-2024 | |
| Caris Mpi, INC. | $36.04 | 2025 | Mi Cancer Seek |
| Morphosys, US INC. | $29.82 | 2023 | Monjuvi |
| Syndax Pharmaceuticals, INC. | $24.62 | 2025 | |
| Immunitybio, INC. | $23.91 | 2025 | |
| Kite Pharma, INC. | $20.32 | 2025 | Yescarta |
| Iovance Biotherapeutics, INC. | $19.42 | 2024 | Amtagvi |
| Genmab U.S., INC. | $18.40 | 2023 | Epkinly |
| Emd Serono, INC. | $18.18 | 2023 | Tepmetko |
| Immunogen, INC. | $17.03 | 2023 | Elahere |
| Azurity Pharmaceuticals, INC. | $15.87 | 2025 | Danziten |
| Apellis Pharmaceuticals, INC. | $15.66 | 2023 | Empaveli |
| Novocure INC. | $15.60 | 2025 | Optune Lua (Novottf-200t) |
| Acrotech Biopharma INC. | $14.65 | 2023 | Beleodaq |
| Tg Therapeutics, INC. | $14.54 | 2021 | |
| Acceleron Pharma, INC. | $14.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.